The OLD Second National Bank of Aurora Has $703,000 Stake in Bristol-Myers Squibb Co. (BMY)

The OLD Second National Bank of Aurora Has $703,000 Stake in Bristol-Myers Squibb Co. (BMY)

OLD Second National Bank of Aurora boosted its position in Bristol-Myers Squibb Co. (NYSE:BMY) by 9.5% during the third quarter, Holdings Channel reports. The fund owned 13,026 shares of the biopharmaceutical company’s stock after buying an additional 1,129 shares during the period. OLD Second National Bank of Aurora’s holdings in Bristol-Myers Squibb were worth $703,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of BMY. Ledyard National Bank boosted its stake in shares of Bristol-Myers Squibb by 5.6% in the third quarter. Ledyard National Bank now owns 22,815 shares of the biopharmaceutical company’s stock worth $1,230,000 after buying an additional 1,209 shares during the last quarter. Boston Advisors LLC boosted its stake in shares of Bristol-Myers Squibb by 10.8% in the third quarter. Boston Advisors LLC now owns 622,617 shares of the biopharmaceutical company’s stock worth $33,572,000 after buying an additional 60,690 shares during the last quarter. Gilman Hill Asset Management LLC boosted its stake in shares of Bristol-Myers Squibb by 11.9% in the third quarter. Gilman Hill Asset Management LLC now owns 17,315 shares of the biopharmaceutical company’s stock worth $934,000 after buying an additional 1,840 shares during the last quarter. Woodley Farra Manion Portfolio Management Inc. boosted its stake in shares of Bristol-Myers Squibb by 4.2% in the third quarter. Woodley Farra Manion Portfolio Management Inc. now owns 5,365 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 215 shares during the last quarter. Finally, Oakworth Capital Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.4% in the third quarter. Oakworth Capital Inc. now owns 9,625 shares of the biopharmaceutical company’s stock worth $519,000 after buying an additional 43 shares during the last quarter. Institutional investors and hedge funds own 68.89% of the company’s stock.

Shares of Bristol-Myers Squibb Co. (NYSE:BMY) traded down 1.03% during mid-day trading on Thursday, hitting $55.49. 7,122,292 shares of the company were exchanged. The firm has a 50 day moving average of $57.82 and a 200 day moving average of $59.28. The company has a market capitalization of $92.74 billion, a price-to-earnings ratio of 27.76 and a beta of 0.94. Bristol-Myers Squibb Co. has a 12-month low of $49.03 and a 12-month high of $77.12.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 27th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.12. The firm earned $4.83 billion during the quarter, compared to the consensus estimate of $4.76 billion. Bristol-Myers Squibb had a return on equity of 28.98% and a net margin of 18.54%. The business’s quarterly revenue was up 21.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.39 earnings per share. Equities research analysts forecast that Bristol-Myers Squibb Co. will post $2.86 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 1st. Shareholders of record on Friday, January 6th will be paid a dividend of $0.39 per share. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Wednesday, January 4th. This represents a $1.56 annualized dividend and a yield of 2.81%. Bristol-Myers Squibb’s payout ratio is presently 76.47%.

A number of analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Monday. Vetr upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.78 target price for the company in a research note on Wednesday, January 11th. Evercore ISI reiterated a “hold” rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Sunday, January 8th. Jefferies Group reiterated a “buy” rating and set a $69.00 target price on shares of Bristol-Myers Squibb in a research note on Thursday, January 5th. Finally, Cowen and Company set a $85.00 target price on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Thursday, December 1st. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $65.89.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).

Related posts

Leave a Comment